These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study. van Schaik IN; Mielke O; Bril V; van Geloven N; Hartung HP; Lewis RA; Sobue G; Lawo JP; Praus M; Durn BL; Cornblath DR; Merkies ISJ; Neurol Neuroimmunol Neuroinflamm; 2019 Sep; 6(5):e590. PubMed ID: 31355323 [TBL] [Abstract][Full Text] [Related]
12. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. van Schaik IN; Bril V; van Geloven N; Hartung HP; Lewis RA; Sobue G; Lawo JP; Praus M; Mielke O; Durn BL; Cornblath DR; Merkies ISJ; Lancet Neurol; 2018 Jan; 17(1):35-46. PubMed ID: 29122523 [TBL] [Abstract][Full Text] [Related]
13. Improvement of hemoglobin levels after a switch from intravenous to subcutaneous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. Markvardsen LH; Christiansen I; Jakobsen J Transfusion; 2016 Oct; 56(10):2443-2448. PubMed ID: 27401495 [TBL] [Abstract][Full Text] [Related]
14. Patient-reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH study. Hartung HP; Mallick R; Bril V; Lewis RA; Sobue G; Lawo JP; Mielke O; Durn BL; Cornblath DR; Merkies ISJ; van Schaik IN; Eur J Neurol; 2020 Jan; 27(1):196-203. PubMed ID: 31400231 [TBL] [Abstract][Full Text] [Related]
15. Quality of life in chronic inflammatory demyelinating polyneuropathy patients treated with subcutaneous immunoglobulin. Ryltoft AK; Al-Zuhairy A; Sindrup SH; Andersen H; Markvardsen LK Acta Neurol Scand; 2020 Dec; 142(6):637-640. PubMed ID: 33404110 [TBL] [Abstract][Full Text] [Related]
16. Long-term treatment with subcutaneous immunoglobulin in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a follow-up period up to 7 years. Gentile L; Mazzeo A; Russo M; Arimatea I; Vita G; Toscano A Sci Rep; 2020 May; 10(1):7910. PubMed ID: 32404895 [TBL] [Abstract][Full Text] [Related]
18. Subcutaneous immunoglobulin therapy given by subcutaneous rapid push vs infusion pump: a retrospective analysis. Shapiro RS Ann Allergy Asthma Immunol; 2013 Jul; 111(1):51-5. PubMed ID: 23806460 [TBL] [Abstract][Full Text] [Related]
19. Immunoglobulin administration for the treatment of CIDP: IVIG or SCIG? Allen JA; Gelinas DF; Freimer M; Runken MC; Wolfe GI J Neurol Sci; 2020 Jan; 408():116497. PubMed ID: 31765922 [TBL] [Abstract][Full Text] [Related]
20. Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy. Lee DH; Linker RA; Paulus W; Schneider-Gold C; Chan A; Gold R Muscle Nerve; 2008 Mar; 37(3):406-9. PubMed ID: 17918749 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]